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Abstract
Purpose: Encourage prediabetes screening, testing, and referral to a CDC-recognized Diabetes
Prevention Program (DPP) as a first-line treatment. Background: The prevalence of diabetes
and prediabetes incidence is highest among Medicare-eligible Washingtonian patients, with
19% and 16%, respectively. DPP results in a 71% reduction of diabetes incidence in 65 years
and older. However, only 3% of healthcare sites screen, test, and refer to DPP. Design: Quality
assessment with a descriptive quantitative evaluation method was conducted using
Retrospective Chart Review for patients who visited Franciscan primary clinics from
08/31/2019 to 08/31/2020. A total of 1250 Medicare patients were extracted from a convenient
sample. Risk factors for prediabetes were identified for 224 patients, including, a first-degree
family history of diabetes, history of hypertension, age, race/ethnicity, physical activity, sex,
history of gestational diabetes, height, and weight and were entered into the online American
Diabetes Association prediabetes risk-test. The number of patients who fulfilled the criteria for
a diagnosis of prediabetes based on Fasting Plasma Glucose, Glycated Hemoglobin A1c and
Random Glucose was 685. Four patients had mixed laboratory results and were excluded; the
remaining 681 were considered for prediabetes management. The number of patients who did
not fulfill laboratory criteria for prediabetes was 565. Results: All the 224 patients (100%) had
risk-test scores of at least 5. The prevalence of misdiagnosis of blood glucose was 45.2%. All
of the 681 patients (100%) meeting requirements of prediabetes were not referred to DPP. Only
26 patients (3.8%) were managed by either metformin (3.1%) or referral to diabetes education
(0.7%). Conclusion: Medicare patients at high risk are not routinely screened, tested, and
managed by DPP, metformin, or diabetes education. Implication: Practice change needs
assessment of PCP awareness about diabetes risk-test, prediabetes laboratory parameters, and
management by referral to DPP.
Key Words: Diabetes Prevention Program, Diabetes Risk-test, Prediabetes Lab Parameters.
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Introduction
Diabetes is a chronic disease that affects how the body metabolizes carbohydrates
resulting in hyperglycemia. The condition is the seventh leading cause of death in the United
States (Centers for Disease Control and Prevention, 2020). There are three main types of
diabetes: type 2 accounting for 90 to 95%, type 1 accounting for 5-10%, and gestational
diabetes. More than 122 million Americans live with diabetes (34.2 million), 20% of whom
are unaware of their diagnosis, “and whereas 88 million live with prediabetes, nearly 85% of
whom are unaware of their diagnosis” (Centers for Disease Control and Prevention, 2020).
The lost wages, time at work, and medical costs in individuals with diabetes are twice as high
as those without diabetes, accounting for $327 billion in health care costs each year (Centers
for Disease Control and Prevention, 2020). Ultimately, the prevention of diabetes saves costs
incurred for treating diabetes and its complications, including retinopathy, peripheral
neuropathy, kidney disease, and cardiovascular diseases (Bansal, 2015). Additionally, early
intervention in older adults prevents or slows the risk of all-cause dementia, Alzheimer
disease and vascular dementia (American Diabetes Association, 2021).
Prediabetes is a precursor state of high blood sugar with glycemic parameters above
normal but not high enough to diagnose diabetes (Bansal, 2015). The definition of
prediabetes lacks uniformity between international organizations. The American Diabetes
Association (ADA) defines prediabetes as impaired fasting plasma glucose level (100125mg/dl), impaired 2-hour oral glucose tolerance test (140-200mg/dl), glycated hemoglobin
A1c of 5.7-6.4%, and random glucose ≥140-199mg/dl (American Diabetes Association,
2014). The World Health Organization (WHO), on the other hand, defines prediabetes with
the same cut-off value for impaired 2-hour oral glucose tolerance test (140-199 mg/dl) but a
higher cut-off value for impaired fasting glucose (110-125mg/dl) (World Health
Organization, 2006). WHO does not consider random glucose and glycated hemoglobin A1c
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as a practical diagnostic test; the latter has potential interference with other hemoglobin
variants such as sickle cell hemoglobin and fetal hemoglobin (World Health Organization,
2006). Like the before ADA, Diabetes Canada 2018 Clinical Practice Guideline defines
prediabetes based on FPG and A1c but with a higher cuff-value (110-125mg/dl) and 6.06.4%, respectively (Punthakee, Goldenberg & Katz, 2018). To confirm the diagnosis of
prediabetes after the initial abnormal test, providers need to repeat testing with the original
screening test, run a different screening test with the initial specimen or collect another
sample (American Diabetes Association, 2014) and rescreen the patient with repeat testing in
3-6 months. If the screening test is within normal range, repeat testing in three years is
recommended (American Diabetes Association, 2021).
The United States Preventative Services Taskforce (USPSTF) recommends screening
for abnormal blood glucose levels between the age of 40 and 70 years in individuals who are
overweight or obese (United States Preventative Services Task Force, 2015), whereas ADA
recommends screening starting at age 45 in all adults regardless of body weight. If screening
is positive for prediabetes, the Centers for Disease Control and Prevention (CDC),
International Diabetes Federation (IDF), ADA, and USPSTF recommend providers offer or
refer patients to an intensive behavioral counseling intervention that promotes a healthful diet
and physical activity. If left unscreened, prediabetic patients develop type II diabetes in 3-8
years (Herman et al., 2015), 50% of which remain undiagnosed and untreated until they
develop complications later in life (International Diabetes Federation, 2017).
Overwhelming evidence from worldwide studies indicates lifestyle intervention with
diet, exercise, or a combination of diet and exercise enhanced by prediabetes education
prevents or delays the risk of developing diabetes. For example, lifestyle intervention reduced
the risk by 46% with exercise alone, by 42% with diet and exercise, and 31% with diet alone
in 577 Chinese individuals over the Da Qing Study's six-year period (Pan et al., 1997).
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Another diabetes prevention study conducted in Europe, among Finish individuals, showed
lifestyle intervention with significant reduction in weight, glycemia, and lipemia over three
years (Lindström et al., 2003). The diabetes prevention program (DPP), a randomized clinical
trial that compared lifestyle intervention with metformin and placebo in multiethnic groups in
3234 US adults with prediabetes, reinforces the importance of lifestyle change in the Chinese
and Finnish studies. The DPP study involved 68% women and 45% minorities. After
followed up for 2.8 years, the DPP reduced the incidence of diabetes by 58% in the lifestyle
intervention group and 31% in the metformin group (Knowler et al., 2002). The reduction of
incidence of diabetes by DPP was highest (71%) in US adults age 65 and older with
prediabetes. However, 90% of older adults are unaware that they have prediabetes (Kalyani,
Corriere, Donner, & Quartuccio, 2018). If a DPP is not available in the area, or patients are
not willing to participate in the program, providers can refer patients to diabetes educators
(Sherr & Lipman, 2013). Primary care providers can also initiate metformin treatment in
prediabetic patients younger than 60 years, or BMI ≥35 kg/m2, and in women with
gestational diabetes mellitus (American Diabetes Association, 2021). Alternatively, they can
refer to medical nutrition therapy or provide a point of care brief counseling (American
Medical Association, 2018).
Problem Statement
In Washington State, diabetes prevalence increased from 4% in 1993 to 9% in 2016,
with the highest (19%) among Medicare eligible patients (Washington State Health
Assessment, 2018). The same survey showed an increase in prediabetes incidence during
2011-2016 from 7 to 8%, with the highest (16%) among Medicare eligible patients.
Unfortunately, the incidence of prediabetes is highest among adults 65 years and older
despite their high awareness of prediabetes in this age group (Washington State Health
Assessment, 2018). One-third of all people in Washington have prediabetes, 70% of which
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could proceed to type 2 diabetes in five years, however most of them are unaware of their
prediabetes status (Diabetes Epidemic and Action Report, 2019).
Background
Diabetes affects more than 25% of Americans aged 65 years and above (Andes et al.,
2019). Among Medicare beneficiaries, diabetes prevalence increased from 23% in 2001 to
32% in 2012 and remained stable until 2015 (Centers for Disease Control and Prevention,
2020). Incidence of diabetes among Medicare patients increased from 3.4% in 2001 to 4 % in
2007 and then steadily declined to 3% in 2015 (Andes et al., 2019). The decline in the
incidence of diabetes in older population is attributed to reduced consumption of dairy
products and sugar-added beverages, and improved physical activity (Kit, et al., 2013; Ussery
et al., 2017). In the last two decades, however, prevalence of diagnosed diabetes in adults
doubled with aging and increased obesity (Center for Disease Control and Prevention, 2020).
Approaches proven to curb progression of prediabetes to diabetes are CDC-approved DPP,
metformin treatment, medical nutrition therapy, diabetes education, or point-of-care brief
counseling on lifestyle change (American Medical Association, 2018).
The National DPP is the most effective evidence-based lifestyle change program that
reduces the incidence of diabetes by 71% among individuals age 65 years and above when
they attain a minimum of 5% weight loss (Kalyani, Corriere, Donner, & Quartuccio, 2018).
The USPSTF found no evidence that the lifestyle change interventions will harm the DPP
participants (US Preventive Services Task Force, 2016). However, over 60% of primary care
providers are not aware of the DPP (Nhim et al., 2018).
In May 2017, the Washington State Institute for Public Policy analysis predicted that
the net benefit from the DPP is $13,000 per participant, including $4,875 of benefit for
taxpayers for each program participant (Diabetes Epidemic and Action Report, 2017).
However, only 8 (3%) healthcare sites out of 243 routinely screen for prediabetes, order lab
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tests, and refer to the DPP in the state of Washington (Diabetes Epidemic and Action Report,
2019), indicating that primary care providers in the rest 97% of healthcare sites do not refer
their patients to DPP.
More than one-quarter of adults with prediabetes express interest in participating in a
diabetes prevention programs, but few are being referred by their primary care providers
(Venkataramani et al., 2019). There is a need to further assess existing practices of
prediabetes screening, testing and referral to the CDC-recognized lifestyle change program
(Nhim et al., 2018) and enhance program referral and access to diabetes prevention programs
(Venkataramani et al., 2019). Practices that used retrospective chart review (RCR) identified
more Medicare-eligible patients with prediabetes and increased referral to DPP than those
using a routine point of care testing alone (Holliday et al., 2019). Additionally, creating a
clinical registry to screen and track patients with prediabetes has resulted in more individuals
with prediabetes being referred to diabetes prevention programs (American Medical
Association, 2017).
Purpose and Aim
The purpose of this project is to encourage screening, testing, and referral to a DPP as
a first-line treatment for prediabetes. The aims of the project through a retrospective chart
review are 1) to determine prediabetes risk-test scores by assessing risk factors for
prediabetes; 2) to determine the prevalence of misdiagnosis of blood glucose levels; and 3) to
assess types of prediabetes management ordered by providers at the Franciscan Primary care
clinics.
Theoretical Framework
The Donabedian model of quality assessment was applied as a conceptual framework
for the project (Donabedian, 1988). An electronic medical record system was used as a
resource to represent the structure of patient care delivery. The providers' routine practice to
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assess for prediabetes risk, order laboratory tests for abnormal glucose, and management of
prediabetes was used as the framework's process. The outcomes of the framework were
misdiagnosis of prediabetes and untreated prediabetes.
Methodology
Study Design
A quality assessment project with a descriptive quantitative evaluation method was
conducted using a RCR (Matt & Matthew, 2013) for patients who visited Franciscan Medical
Group (FMG) primary clinics between 08/31/2019 to 08/31/2020.
Setting
Catholic Health Initiative (CHI) Franciscan Healthcare System of Washington has 29
primary care clinics served by an estimated 205 primary care providers of FMG (Franciscan
Medical Group). Out of which 165 of the providers are physicians, and the remaining 40 are
nurse practitioners and physician assistants. The number of diabetes educators who serve
within the healthcare system is estimated to be 8-10. The total number of Medicare patients
who visited the primary clinics within the healthcare system between 2013-2020 was 18752,
with an average annual patient number of 2344.
Sample
The inclusion criteria included age 65 years and above, body mass index (BMI)≥25
kg/m2 (≥23 kg/m2, if Asian), Medicare or Medicare Advantage health plan, and laboratory
test results within the last one year of Fasting Plasma Glucose (FPG) range within 100125mg/dl, or A1c range within 5.7%-6.4%, or 2-hour Oral Glucose Tolerance Test (OGTT)
range within 140-200 mg/dl), or history of gestational diabetes, and both sexes of all
racial/ethnic groups. Exclusion criteria included those individuals with type 1 or type 2
diabetes, end-stage renal disease or long-term (current) use of insulin (Appendix A; Center
for Medicare and Medicaid Services, 2018). Published literature indicates a minimum of 5-10
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chart reviews per variable is required to obtain results that are likely to be both valid and
clinically useful (Johnston et al., 2019). Johnson et al. further indicated that 100 retrospective
chart reviews are sufficient for summarizing prediabetes management categories.
Demographic
The majority of 1250 Medicare patients reviewed in this quality assessment project
were White or Caucasian, 1066 (85.28%), followed by Asians, Blacks, and Native Hawaiian,
and they were overweight, obese, or extremely obese (Table 1).
Table 1.0
Health and Demographic Characteristics of Medicare Patients (n=1250)
Characteristics
Sex
Race

Ethnicity

Body Max
Index

Female
Male
White/Caucasian
Asians
Blacks
Declined
Unable to
determine
Other
Native Hawaiian
Not Hispanic or
Latino
Hispanic
declined
Unable to
determine
Overweight
(25-29.9)
Obese (30-34.9)
extremely Obese
(≥35)

n
679
571
1066
47
42
38
25

%
54.32
45.68
85.28
3.76
3.36
3.04
2

21
7
1175

1.68
0.56
94

33
25
17

2.64
2
1.36

560

44.8

405
285

32.4
22.8

A convenience sample of 18,752, Medicare patient data was retrieved from Epic, an
electronic charting system. Out of 18,752 Medicare patients, 17,502 were excluded for test
results older than one year, diagnosis of type 1 or type 2 diabetes, long-term (current) insulin
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use, or end-stage renal disease. The remaining 1,250 Medicare patients who sought care at
CHI Franciscan Primary Care Clinics within the last year between 08/31/2019 to 08/31/2020.
Out of 1,250 Medicare patients, 565 were excluded from consideration for prediabetes
management because they had either normal A1c (<5.7%, n=323), A1c within diabetes range
(>6.4%, n=17), or were not tested by A1c (n=225). None of the 565 patients were tested with
2-hour OGTT for prediabetes. Out of the 225 patients not tested by A1c, only one patient was
tested by FPG and had normal blood glucose result; the remaining, 224 patients were tested
only with random glucose and assessed for CDC prediabetes risk-test score. Samples
collected to assess for prediabetes risk were first-degree family history of diabetes, history of
hypertension, age, race/ethnicity, physical activity, sex, height, and weight.
A total of 685 out of the 1250 patients fulfilled laboratory inclusion criteria for
prediabetes defined as FPG 100-125mg/dl or A1c 5.7%-6.4%. Four patients were excluded
for having A1c levels within the diabetes range; the remaining 681 patients were considered
for prediabetes management. None of these patients were tested with 2-hour OGTT for
prediabetes.
Data Collection Procedure
Before collection of data, the Institutional Review Board (IRB) exempt approval was
obtained from the CHI Franciscan Healthcare System to protect human subjects. The
retrospective health record data was collected anonymously with no patient data identifiers.
With data analysts' help at the CHI healthcare system, inclusion and exclusion criteria were
entered into the Epic electronic health record system. The data analyst exported the data into
an excel spreadsheet, coded the medical record number (MRN) of each patient with a specific
identification number, and then removed patient identifiers.
Data on, 1250, Medicare patients who visited primary care clinics of the CHI
Franciscan health care system within the last year between 08/31/2019 and 08/31/2020 was
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filtered using an excel spreadsheet. Medicare patients (n=681) who fulfilled the inclusion
criteria for prediabetes management were filtered within excel by the provider’s plan and
categorized into prediabetes management types: DPP, Metformin, diabetes education, or
medical nutrition therapy (figure 1 & figure 2).
Medicare patients (n=565) who did not fulfill laboratory inclusion criteria for
prediabetes were identified by laboratory test as having A1c in diabetic range, normal A1c,
no A1c test, normal fasting plasma glucose, random glucose within diabetes range, or no
laboratory glucose test within the last one year. However, these patients were assessed for
misdiagnosis of prediabetes by filtering based on the laboratory test result and International
Classification of Diseases -Tenth Revision (ICD-10 codes) such as R73.01, R73.02, R73.03,
R73.09 which were retrospectively entered into Epic by providers. Out of the 565 Medicare
patients, 224 were tested only by random glucose or were not tested (figure 1). The 224 were
filtered within Excel by the risk factors for prediabetes, and the risk factors were entered into
the online CDC prediabetes risk-test calculator (appendix B), and online scores
from https://www.diabetes.org/risk-test were manually entered into an excel spreadsheet
(figure 1 & figure 2).
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Chart Reporting Tool
Assess risk factors for prediabetes

Online ADA Prediabetes risk-test score
https://www.diabetes.org/risk-test

Review Logical Observation Identifiers Names (LOIN)
Identify abnormal glucose lab test results

Review Provider’s Assessment (ICD-9 and ICD-10 codes)
Assess diagnosis of prediabetes

Review Provider’s Plan

Categorize as referral to DPP, Diabetes Education, Medical Nutrition Therapy, metformin treatment, a brief
lifestyle change counseling.

Figure 1. Steps in Data Collection Procedure.
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Total
Medicare
patients
Visited CHI
Primary
Care,
Washington
State, 20132020

Diagnosis
with
abnormal
blood
glucose

15

lab inclusion
critieria for
prediabetes

fulfilled (n=685)

A1c 5-7-6.4% (n=672)

random glucose 140199mg/dl (n=8)
within 1 year,
08/31/201908/31/2020 (n=1250)

Fasting plasma glucose
100-125mg/dl (n=1)

A1c>6.4% (n=4),
excluded
n=18752
not fulfilled (n=565),
but diagnosis given as
prediabetes
prior to 08/31/2019
(n=17,502), excluded.

A1c>6.4% (n=17),
diabetes

normal A1c (<5.7%,
n=323)

Normal fasting plasma
glucose <100mg/dl
(n=1)
<140mg/dl (n=221)
Random glucose
>200mg/dl (n=2),
diabetes
no lab test (n=1)

Figure 2. Flowchart of sample collection procedure
Data Analysis
Data was exported from Epic into an Excel spreadsheet. All study subjects with
missing data and outliers were removed from data analysis during the cleaning process. Mode
and weighted average scores as central tendency measures were calculated for prediabetes
risk-test score by demographic characteristics of gender and race/ethnicity. Frequency and
percentage of Medicare patients with prediabetes risk-test score of 5 or more for whom
providers ordered laboratory screening tests (A1c, FPG, or 2hr-OGTT) were calculated.
Mode as a measure of central tendency and percentages were calculated for prediabetes
management types (DPP, Metformin, Diabetes Education, or a brief lifestyle counseling)
ordered by providers. Similarly, mode as a measure of central tendency and percentage of
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misdiagnosis of prediabetes by ICD-10 and laboratory test categories were calculated. The
prevalence of misdiagnosis by ICD-10 codes and glucose laboratory tests was calculated.
Result
Prediabetes Risk-Test Score
All 224 (100%) Medicare patients were found to have CDC-prediabetes risk-test
scores of 5 or more with 7.2, 6.8, and 7.5 weighted average scores for both sexes, females,
and males respectively (table 2). None of the 224 patients (100%) were laboratory screened
for prediabetes by A1c, FPG, or 2hr-OGTT (Table 2). The frequency of prediabetes score
steadily increases as a score increases from 5 to 7 and decreases as the score increases from 7
to 9 in both genders with mode score of 7 (figure 3). As the prediabetes risk-test score
increases from 7 to 9, within the same score, a greater number of males than females tend to
be at risk for developing diabetes (figure 4). The majority of Medicare patients with scores 5
or more are white (n=197, 87.95%) followed by Asian (n=8, 3.57%), other race (n=6,
2.68%), declined (n=6, 2.68%), black (n=4, 1.79%), unable to determine race (n=3, 1.34%)
(table 3, appendix D).
Table 2.0
Medicare Patients Eligible for Prediabetes Screening by Laboratory Test
Number eligible for
prediabetes Risk-Test
Score

Number with
Prediabetes
risk-test score
≥5

% eligible for
screening by
A1c, FPG, or
OGTT-2hr

224

224

100

% screened by
A1c, FPG, and 2hrOGTT
0
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50
43

45
39

40
35

35

FREQUENCY

35

30
23

25

19

20

Male
14

15

10

Female

9
5

5

2

0
5

6

7

8

9

PREDIABETES RISK-TEST SCORE

Figure 3. Frequency of Prediabetes Risk-Test Score Comparison Between
Male and Female Medicare Patients.

90

82

79

80

71

70

60

Percent

60
48

50

52

40

40
30
20

Female

29

Male

21

18

10
0
5

6

7

8

9

Prediabetes risk-test score

Figure 4. Percentage of Medicare Patients for each prediabetes risk-test score by
gender
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Table 3.0
Prediabetes Risk-Test Score by Race
Prediabete
s risk-test
score
5
6
7
8
9

Asia
n

Whit
e

Blac
k

1
2
4
1
0

8
45
69
52
23

Total

8

%
Weighte
d
average

7.2

othe
r

decline
d

tota
l

0
1
1
2
0

unable to
determin
e
1
0
1
1
0

1
0
4
0
1

0
1
3
2
0

11
49
82
58
24

197

4

3

6

6

224

3.5

87.95

1.79

1.34

2.68

2.68

6.6

7.2

7.3

6.7

7.0

7.2

%

4.9
21.9
36.6
25.9
10.7
1

Misdiagnosis of Blood Glucose Level
The prevalence of misdiagnosis of blood glucose level by either ICD-10 code or
laboratory test was 45.2% (n=565). Most (n=201, 35.58%) of the misdiagnosis of blood
glucose level was labeled as impaired fasting glucose with ICD-10 code R73.01, followed by
other abnormal glucose (n=173, 30.62%, R73.09), prediabetes (n=163, 29.03%, R73.03), and
impaired oral glucose (n=27, 4.78%, R73.02) (table 4, figure 5). Normal A1c level was the
most (n=323, 57.17%) laboratory test misdiagnosed as abnormal blood glucose followed by
normal random glucose (n=221, 39.02%), A1c>6.4% (n=17,3.01%), normal fasting plasma
glucose (n=1, 0.18%) and diagnosis without laboratory test (n=1, 018%) (table 4, figure 6).
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250
201

Frequency

200

173

164

150
100
50

27

0
R73.01 (Impaired
fasting glucose)

R73.09 (other
abnormal glucose)

R73.03
(Prediabetes)

R73.02 (Impaired
Oral Glucose
Tolerance)

ICD-10 codes

Figure 5. Frequency Distribution of Misdiagnosis of Blood Glucose Level by
ICD-10 Codes (n=565).
350

323

300

Frequency

250

221

200
150
100
50

17

2

1

1

0

Laboratory Test Categories

Figure 6. Frequency Distribution of Misdiagnosis of Blood Glucose Level by
Laboratory Test (n=565).
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Table 4.0
Misdiagnosis of Blood Glucose Level in Medicare Patients by ICD-10 and Laboratory Test
Categories.
Lab Categories
R73.01
A1c
test

No
A1c
test

Normal
A1c
(<5.7%)
Diabetic
range
A1c
(>6.4%)
Normal
FPG
(<100m
g/dl)
Normal
Random
Glucose
(<140m
g/dl)
Diabetic
Range
Random
Glucose(
>200mg/
dl)
No lab
test
Total
%

ICD-10 codes
R73.02 R73.03
R73.09

Total

%

108

20

70

125

323

57.17

8

1

1

7

17

3.01

0

1

0

0

1

0.18

85

5

91

40

221

39.12

0

0

1

1

2

0.35

0

0

1

0

1

0.18

201
35.58

27
4.78

164
29.03

173
30.62

565

Note. R73.01, Impaired fasting glucose; R73.09, other abnormal glucose; R73.03,
Prediabetes; R73.02, Impaired Oral Glucose Tolerance.
Management of Prediabetes
All of Medicare patients (n=681, 100%) with prediabetes, as determined by, were not
referred to a DPP, or individualized medical nutrition therapy. Only 21 patients (3.08%) were
treated with metformin and 5 patients (0.73%) were referred to Diabetes Education (table 5).
Due to restricted access to patients’ charts, the number of Medicare patients who received a
brief lifestyle counseling could not counted (table 5).
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Table 5.0.
Categories of prediabetes Management

Prediabetes Management Categories
comment
Eligible for
management of
prediabetes

DPP

Metformin Diabetes
Educatio
n

Medical Brief
Nutrition lifestyle
counseling

Number

0

21

0

681

5

unable to
determine

excluded
4 out of
685 for
having
A1c>6.4
%

%
3.8
0
3.1
0.7
0
managed
Note. Laboratory criteria to be eligible for management of prediabetes are A1c 5.7-6.4%,
FPG 100-125mg/dl, or Random glucose 140-199mg/dl.

Number per 681 patients per year

25

20

21

15
10

5
5
0

0

0

Medical Nutrition

Brief Lifestle
Counseling

0
DPP

Metformin

Diabetes
Education

Prediabetes Management

Figure 8. Medicare patients who received prediabetes management between 08/31/2019
to 08/31/2020.

Aiding Screening, Diagnosis, and Management of Prediabetes

19%

0%

22

DPP
Metformin

Diabetes Edu
Medical Nutrition

81%

Brief Lifestle Counseling

Figure 9. Medicare Patients (n=26) who received prediabetes management in primary
care setting between 08/31/2019 to 08/31/2020.
Discussion
Prediabetes Risk-Test Score
The current quality assessment project’s data indicates that all 224 high-risk Medicare
patients who visited CHI Franciscan primary clinics were not screened for prediabetes with
the CDC/ADA diabetes risk test. This finding reflects a national survey report that only 27%
of primary care providers (n=1256), including MDs and ARNPs, use the risk test to screen
for prediabetes (Nhim et al., 2018) and only 6% of PCPs correctly identified all the risk
factors that warrants prediabetes screening (Tseng et al., 2017). More than 50% (112 out of
224) of the Medicare patients with the ADA Diabetes Risk test score of 5 or more, were not
diagnosed with prediabetes (Ward, Hopkins & Shealy, 2021). This finding is in-line with the
previous study that showed lack of screening in a primary care setting is one reason for
delays in initiation or intensification of evidence-based treatment for diabetes (Grant et al.,
2004). The low screening for prediabetes indicates an urgent need to use the CDC/ADA
diabetes risk test to help primary care providers identify high-risk patients to curb epidemics
of diabetes (Ward, Hopkins & Shealy, 2021).
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Misdiagnosis of Blood Glucose Level
The high prevalence (45.2%) of misdiagnosis of prediabetes could be due to the lack
of knowledge around recommended laboratory parameters of prediabetes and incorrect use of
ICD-10 codes as demonstrated by high misinterpretation of normal blood glucose level per
ADA criteria (Alc<5.7% and random glucose<140mg/dl) as abnormal. The high prevalence
(45.2%) of misdiagnosis of prediabetes found in this project is supported by another study
where a survey regarding PCP knowledge indicated that only 17% correctly identified
laboratory parameters for prediabetes based on FPG and A1c (Tseng et al., 2017). The lack of
knowledge of PCPs about laboratory parameters could be due to inadequate preparation of
undergraduate medical students (Khan, Wozniak, & Kirley, 2019). Moreover, the lack of
uniformity in laboratory cut-off values of prediabetes between various organizations such as
WHO and ADA (Bansal, 2015) and Diabetes Canada (Punthakee, Goldenberg & Katz, 2018)
could add inconsistency in interpreting laboratory parameters and use of ICD-10 codes.
Misdiagnosis may unnecessarily result in overdiagnoses that could burden society in return
for limited clinical value (Yudkin & Montori, 2014).
Management of Prediabetes
The majority (96.2%) of the Medicare patients with prediabetes were not managed by
referral to a DPP, metformin, referral to diabetes education, or medical nutritional therapy.
All these patients were eligible for in-person or online DPP, the most effective evidencebased lifestyle intervention known to prevent progression of prediabetes into diabetes. It is
important to note that Medicare part B and Medicare Advantage cover costs related to
glucose laboratory test screenings twice year and participation in the Medicare DPP (Center
for Medicare and Medicaid Services, 2019). The lack of prediabetes management is
consistent with a previous survey with 36 clinicians in a family medicine clinic where none
referred patients with prediabetes to a DPP (Keck et al., 2019). The current zero referral is
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also supported by a national study that showed more than 75% of primary care providers do
not refer to a DPP. This is attributed to a lack of awareness about the program's existence
(Nhim et al., 2018) and the role of lifestyle change in prevention of diabetes (Khan, Wozniak
& Kirley, 2019). The national survey by Nhim et al. showed 62% of primary care providers
are not aware of the DPP, and 81% are not knowledgeable about the STAT (Screen, Test, Act
Today) toolkit, use of which is associated with increased referral to the lifestyle change
program.
Once started, based on the Diabetes Prevention Program Outcome Study (DPPOS),
metformin therapy should continue for the long-term, especially in prediabetic patients with a
higher cut-off value of FPG 110-125 mg/dl and A1c 6.0-6.5% (Davidson, 2020). Providers
should be aware that withdrawal of metformin treatment for a 1-to 2-week period may result
in 64% more at risk of developing diabetes than those who have not started it (Diabetes
Prevention Program Research Group, 2003).
Conclusion
This quality assessment project indicates potential need to improve clinical practice
related to referral for prediabetes and patient outcomes within the CHI primary care clinics.
The data showed that FMG primary care providers do not routinely screen for prediabetes
using ADA/CDC prediabetes risk-test, order recommended laboratory tests for high-risk
patients, refer confirmed prediabetes patients to the CDC-approved DPP suppliers, treat with
metformin, and/or refer to diabetes education. As a result, 100% of CHI Medicare patients
eligible for screening remained unscreened, making them at risk for undetected prediabetes or
diabetes and its complications. FMG providers need to use consistent laboratory tests
recommended by ADA with the correct interpretation of the results and correct ICD-10 codes
to avoid the current high rate of misdiagnosis of prediabetes. Finally, FMG is encouraged to
use these findings from the quality assessment to raise awareness of PCPs about the practice
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gap, use of DPP as a first-line treatment for prediabetes in Medicare patients. The FMG is
also encouraged to start a pilot quality improvement project with selected providers and
primary care clinics to implement a trial of the Plan-Do-Study-Act cycle (Knudsen et al.,
2019) of routine prediabetes screening, testing, and clinic-to-DPP referral (Appendix C).
Providers can take advantage of the already established memorandum of understanding and
business associate agreement between CHI Franciscan medical clinic and YMCA, the DPP
supplier.
Limitations
The project has some limitations:
1. The investigator could not detect undiagnosed cases, patients who fulfilled laboratory
criteria for prediabetes but not given the diagnosis, because ICD-10 codes used to
extract diagnosis of abnormal blood levels resulted only in diagnosed cases.
2. The restricted access to patient charts limited access to provider's note on brief
lifestyle counseling for prediabetes.
3. Most patient charts extracted retrospectively did not contain physical activity
information. It is unclear whether a history of physical activity was not asked or not
documented during the patient visit. As a result, the investigator could not find
physical activity details in terms of duration per session and number of sessions per
week in the patient's chart.
4. A survey might have been helpful to assess providers' knowledge and awareness on
ADA/CDC risk-test, laboratory parameters of prediabetes, and DPP's availability.
However, a follow-up survey was not part of the study protocol.
5. Although 2hr-OGTT is the best diagnostic test for prediabetes diagnosis, based on a
total of 7412 randomly selected undiagnosed adults from the National Health and
Nutrition Examination Survey (Tucker, 2020), the current findings heavily relied on
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results of A1c, FPG, and random glucose tests. None of the study subjects had
laboratory values for OGTT, even though the test agreement with A1c is only 25%
and with FPG, 33.4% (Tucker, 2020). To avoid under or over-diagnosis of
prediabetes, combining two of the three tests (A1c, OGTT-2hr, and FPG) produces a
reliable diagnostic result (Gonzalez et al., 2020).
6. Data on medical nutrition therapy was not found likely due to lack of reimbursement
from Medicare for Medicare patients with prediabetes unless A1c is 6.4 or greater.
7. Finally, this project's findings are not generalizable as the samples are not
representative of all Medicare patients of all races, ethnicity, or gender.
Implications
The findings indicate that FMG primary care providers are not fully utilizing the best
evidence-based diabetes prevention strategies. FMG needs to encourage their providers to
screen, test, and refer high-risk prediabetes patients to DPP suppliers within their area. The
lack of routine screening and testing for prediabetes contributes to the underutilization of
diabetes educators who are skilled professionals able to reduce the risk of developing type II
diabetes. The high prevalence of misdiagnoses of prediabetes blood glucose levels, suggests
that reviewing current guidelines and reference ranges for fasting plasma glucose, A1c, oral
glucose tolerance test, and random glucose tests would be beneficial for providers. Assigning
the correct ICD-10 codes during the patient visit for abnormal blood glucose levels specific
to the laboratory test would further improve diagnosis. Increasing provider's awareness of
identifying high-risk patients using ADA/CDC prediabetes risk-test tool, preferably a
screening tool embedded within the Epic, would prompt providers to place an order for
specific recommended prediabetes blood glucose tests and increase referral of those Medicare
patients with prediabetes to DDP suppliers, ultimately decreasing the incidence of diabetes at
CHI.
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Appendix A. Eligibility Criteria

Medicare Diabetes Prevention Program (MDPP)
Beneficiary Eligibility Fact Sheet
This checklist contains a summary of MDPP beneficiary eligibility requirements, as well as tips that MDPP suppliers
can use to determine beneficiary eligibility. A full list of the beneficiary eligibility requirements can be found in the
CY18 Medicare Physician Fee Schedule final rule at 42 C.F.R. 410.79(c).

REQUIREMENTS TO START SERVICES
To start MDPP services, beneficiaries must have:
Medicare Part B coverage through Original Medicare (Fee-for-Service) or a Medicare Advantage (MA) plan.
Results from one of three blood tests conducted within one year before the first core session:
•

Hemoglobin A1c test with a value of 5.7-6.4%

•

Fasting plasma glucose test with a value of 110-125 mg/dl

•

Oral glucose tolerance test with a value of 140-199 mg/dl

A body mass index (BMI) of at least 25, 23 if self-identified as Asian.
No history of type 1 or type 2 diabetes, with the exception of gestational diabetes.
No End Stage Renal Disease (ESRD).
Not received MDPP services previously.

REQUIREMENTS TO CONTINUE SERVICES
Represents when a beneficiary must meet a specific performance goal (i.e., attendance, weight loss) to be eligible to
continue having coverage of services.

CORE SESSIONS

16 sessions

Months 0-6

ONGOING MAINTENANCE SESSIONS

CORE MAINTENANCE SESSIONS

Interval 1

Interval 2

Interval 1

Interval 2

Interval 3

Interval 4

3 sessions

3 sessions

3 sessions

3 sessions

3 sessions

3 sessions

Months 7-12

Eligibility for Coverage of Core and Core Maintenance
Sessions
• Eligible beneficiaries can participate in core and core
maintenance sessions in the first 12 months
regardless of attendance or weight loss.

Months 13-24

Eligibility for Coverage of Ongoing Maintenance Sessions
• Interval 1: Beneficiaries must attend at least one inperson core maintenance session during months 10-12
and achieve or maintain 5% weight loss to proceed to
interval 1.
• Intervals 2-4: Beneficiaries must attend at least two
sessions (at least one in-person) in the previous interval
and maintain 5% weight loss to go on to the next
interval.

Note: An interval is a 3-month period tied to beneficiary performance and payment.
1
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Appendix B. Prediabetes Risk Test

Prediabetes
Risk Test
1. How old are you?

Writ e your score in
t he b oxes below

Younger than 40 years (0 point s)
40–49 years (1 point)
50–59 years (2 point s)
60 years or older (3 point s)

2. Are you a man or a w oman?
Man (1 point)

Woman (0 point s)

3. If you are a w oman, have you ever been
diagnosed w it h gest at ional diabet es?
Yes (1 point)

No (0 point s)

4. Do you have a mot her, f at her,
sist er, or brot her w it h diabet es?
Yes (1 point)

No (0 point s)

5. Have you ever been diagnosed
w it h high blood pressure?
Yes (1 point)

No (0 point s)

6. Are you physically act ive?
Yes (0 point s)

No (1 point)

Height
4' 10"

119-142

143-190

191+

4' 11"

124-147

148-197

198+

5' 0"

128-152

153-203

204+

5' 1"

132-157

158-210

211+

5' 2"

136-163

164-217

218+

5' 3"

141-168

169-224

225+

5' 4"

145-173

174-231

232+

5' 5"

150-179

180-239

240+

5' 6"

155-185

186-246

247+

5' 7"

159-190

191-254

255+

5' 8"

164-196

197-261

262+

5' 9"

169-202

203-269

270+

5' 10"

174-208

209-277

278+

5' 11"

179-214

215-285

286+

6' 0"

184-220

221-293

294+

6' 1"

189-226

227-301

302+

6' 2"

194-232

233-310

311+

6' 3"

200-239

240-318

319+

6' 4"

7. What is your w eight cat egor y?

Weight (lbs.)

205-245

246-327

328+

1 Point

2 Point s

3 Point s

You weigh less than the 1 Point column
(0 points)

(See chart at right)

Tot al score:

Adapted from Bang et al., Ann Intern Med 151:775-783, 2009. Original algorithm
was validated without gestational diabetes as part of t he model.

If you scored 5 or higher
You are at increased risk for having prediabetes and are at high risk for t ype 2 diabetes. However, only your doctor can tell for sure if you
have type 2 diabetes or prediabetes, a condition in which blood sugar levels are higher than normal but not high enough yet to be diagnosed
as t ype 2 diabetes. Talk t o your doct or t o see if addit ional t est ing is needed.
risk for prediabetes and type 2 diabetes. Also, if you are Asian American, you are at increased risk for type 2 diabetes at a lower weight (about
15 pounds lower than weights in the 1 Point column). Talk to your doctor to see if you should have your blood sugar tested.

CS300699-A

You can reduce your risk for t ype 2 diabet es
Find out how you can reverse prediabetes and prevent or delay
type 2 diabetes through a CDC-recognized lifest yle change pr ogram
at https://www.cdc.gov/diabetes/prevention/lifestyle-program.

Risk Test provided by the American Diabetes Association
and the Centers for Disease Control and Prevention.
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Appendix C. Diabetes Prevention Program Referral Template

National Diabetes Prevention Program (National
DPP) lifestyle change program referral template
This resource can be used as a guide for creating a form to refer patients from clinical settings to a National DPP lifestyle
change program provider. The elements noted comprise key information to include in a referral and a sample template is
also displayed below.
•

Patient information: Name, contact information (address, phone, email), birth date/age, gender , health insurance,
employer, preferred method of contact, preferred time to contact.
Health care provider information: Physician/provider name, practice name, practice contact name, practice
information (address, phone, fax, etc.)
Other information: Date of referral, authorization information (language that meets your organization’ s specific legal
requirements for privacy and security, etc.), eligibility for program information (patient body mass index, medical
history and blood test results), signatures of physician/ordering provider and patient OR patient representative.

•
•

This resource is provided for informational purposes only and does not constitute legal advice. Please consult with a
qualiﬁed legal advisor to create a resource for use within your organization.
Send to (program name):

Fax/Email:

Pat ient informat ion

Address

Gender

City

Birth date (mm/dd/yy)

State

Employer

ZIP code

Preferred method of contact

Phone

Preferred time to contact

Health Insurance

m
Sa

Name

Healt h care provider inform ation

Physician/NP/PA name

Address

Practice name

City

Phone

State

Fax

ZIP code

Date: _________________

Health care provider signature: __________________________________________

Authorization for release of health information [Insert your o rganization’s speciﬁ c legal language here.]

Referral eligibility information:
Criteria
¨
¨

Result

Body Mass Index (BMI)
Blood test
• Hemoglobin A1C

Eligibility = ≥25 (≥23 if Asian)

_____________________

5.7-6.4%

_____________________

•

Fasting plasma glucose

100-125 mg/dL

_____________________

•

2-hour oral glucose tolerance test

140-199 mg/dL

_____________________

Date of blood test (mm/dd/yy):
¨

History of Gestational Diabetes

Date: _________________

e
pl

Reference range

________________________________

Patient or representat ive signature: _____________________________________

(Basis of representative’s authority to sign on behalf of patient: ____________________________________________ )

Copyright © 2020. American Medical Association. All rights r eserved. 18-299724
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Appendix D. Prediabetes Score Frequency by Race
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Frequency of Prediabetic Score Among Racial/Ethnic Groups (n=224)

